Indirect Costs Associated With Pneumococcal Disease: A Global Targeted Literature Review

Author(s)

Min Huang, PhD1, Jipan Xie, MD, PhD2, Walter Albert Orenstein, MD3, Hela Romdhani, PhD4, Yan Song, PhD5, Elamin Elbasha, BSc, MA, PhD6, Matthew Kelly, MD, MPH7.
1Sr. Principal Scientist, Merck & Co. Inc, North Wales, PA, USA, 2XL Source, Inc., Los Angeles, CA, USA, 3School of Medicine, Emory University, Atlanta, GA, USA, 4Analysis Group, Montreal, QC, Canada, 5Analysis Group, Boston, MA, USA, 6Merck & Co. Inc, West Point, PA, USA, 7Arkansas Children’s Hospital, Little Rock, AR, USA.
OBJECTIVES: We sought to synthesize existing evidence on indirect costs associated with acute episodes of pneumococcal disease (PD).
METHODS: A targeted literature review was conducted globally using MEDLINE (2010-2024) to identify original studies estimating indirect cost per PD episode. Mean costs were extracted and adjusted to 2024 USD using currency conversion rates and the U.S. Consumer Price Index. Results were summarized by PD category in children (0 ̶ 17 years) and adults (≥18 years).
RESULTS: Eleven studies were identified — eight in children and three in adults. All studies used the human capital approach to estimate productivity loss associated with morbidity. Among children, one study each reported mean cost of caregiver productivity loss per episode of invasive pneumococcal disease (IPD) ($217), inpatient pneumonia ($430), and unspecified pneumonia ($219). All three studies focused solely on absenteeism, and the studies on IPD and inpatient pneumonia considered absenteeism during hospitalization only. Five studies estimated indirect cost for acute otitis media (AOM): one focused on absenteeism only ($105), while the remaining four also included presenteeism, unpaid work, and loss of leisure time [median (range) of mean costs: $698 ($264-1,221)]. Key drivers of cost variability included differences in the components of productivity loss, productivity loss time, and wage across countries, and episode definitions. All three adult studies focused on pneumonia and considered absenteeism only. The median (range) cost per episode was $4,523 ($736-9,503) for inpatient pneumonia (n=3) and $2,270 ($1,908-2,631) for outpatient pneumonia (n=2). Cost variability was mostly driven by differences in wages and episode definitions.
CONCLUSIONS: Productivity loss represents a substantial economic burden among children with AOM and adults with pneumonia. However, existing evidence for IPD and pneumonia in children is limited. The substantial variability across studies highlights heterogeneity in methodologies. Future studies should address these gaps and capture all relevant productivity loss.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

EE551

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Infectious Disease (non-vaccine)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×